Inhibitors of cyclic nucleotide phosphodiesterases (PDEs), which regulate concentrations of the key signalling intermediates cAMP and cGMP, are well established as drugs for disorders including erectile dysfunction and pulmonary hypertension. This article discusses how recent understanding of the roles of individual PDEs in regulating the subcellular compartmentalization of specific cyclic nucleotide signalling pathways is aiding the development of more sophisticated strategies to target individual PDE variants.
- Donald H. Maurice
- Hengming Ke
- Vincent C. Manganiello
